Medicines Company discontinues MDCO-2010 Phase 2b study
The MDCO-2010 was being developed as an intravenous antifibrinolytic drug for the reduction of blood loss during surgery. Although the cause of the safety issues and any potential
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.